EGFR and melanoma: Recent studies show that YAP1 promotes resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in lung cancer [11] or inhibitors of the Raf–mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase MEK–ERK–MAPK signaling pathway in BRAF- and RAS-mutant human melanoma patients [12].